Kisspeptin and Fertility: The Research

The short version

Kisspeptin and fertility is where this peptide has earned its most serious human attention. Because kisspeptin is the switch that turns on the reproductive hormones, giving it can do three fertility-relevant things in research settings. First, it can trigger eggs to mature for IVF — and because it sets off the body's own brief surge rather than a long-lasting drug, it does this without causing OHSS, the dangerous over-stimulation that the standard trigger can. Second, it can restart the natural hormone rhythm in women whose periods have stopped from stress, low body weight or heavy training (hypothalamic amenorrhea). Third, it sits at the center of PCOS, where the same hormone runs too high.

All of this is investigational — no health agency has approved kisspeptin for fertility or anything else, and it is not a supplement. The studies below used pharmaceutical-grade peptide under medical supervision, and the doses are reported only as research, never as something to take.

Triggering egg maturation in IVF without OHSS

The headline fertility result is safety with efficacy. In a Phase 2 randomized trial of 60 women at high risk of OHSS, a single subcutaneous dose of kisspeptin-54 (3.2-12.8 nmol/kg) triggered oocyte maturation in 95% of women, with no case of moderate, severe or critical OHSS at any dose; the highest live-birth rate, 62%, followed the 9.6 nmol/kg dose ^[5]. The reason this matters: standard IVF triggers impose a long, strong hormonal drive that can tip high-responders into OHSS, whereas kisspeptin prompts the brain to release its own short-lived LH surge, maturing the eggs without the prolonged over-stimulation ^[5]. A 2025 study added that the trigger can be delivered intranasally, with kisspeptin-54 (12.8 nmol/kg) raising LH in healthy women and others without adverse events ^[6].

Restoring ovulation in hypothalamic amenorrhea

When periods stop because the brain's GnRH pulses are suppressed — often from low energy availability, heavy exercise or stress — kisspeptin can restart the rhythm. Continuous intravenous kisspeptin-54 (0.01-1.00 nmol/kg/h) restored pulsatile LH secretion in affected women: LH pulses rose from 1.6 to 5.0 per 8 hours (about three-fold) and pulse secretory mass from 3.92 to 23.44 IU/L (about six-fold) versus vehicle ^[4]. The catch is dose-dependent — the highest infusion rate produced tachyphylaxis, the fade-out that limits continuous dosing ^[4]. Related work points to low neurokinin B, a regulator of kisspeptin release, as a contributor to functional hypothalamic amenorrhea, with neurokinin B significantly reduced in affected women ^[12].

Kisspeptin, fertility and PCOS

In polycystic ovary syndrome — a leading cause of infertility — kisspeptin runs in the opposite direction: too high rather than too low. A meta-analysis of nine studies (n=1,282) found serum kisspeptin significantly elevated in women with PCOS versus controls (standardized mean difference 0.57, 95% CI 0.32-0.82), tracking with LH and testosterone ^[8], and a focused review reported the elevation most prominently in high-LH PCOS phenotypes ^[9]. The fertility implication is mechanistic: overactive kisspeptin signaling appears to drive the excess LH and androgen output that disrupts ovulation in PCOS, which is why kisspeptin is studied here as a biomarker and a clue to the disordered neuroendocrinology rather than as a treatment ^[14]. Across all three fertility threads — IVF, amenorrhea and PCOS — the throughline is that kisspeptin is the upstream switch, and fertility tracks with whether that switch is firing too little or too much.